Thank you for your interest in receiving Gilead Sciences communications. Gilead Sciences shall constantly strive to make sure to only send information that is of high quality and relevant to you.

With your permission, and by clicking on the below button, you consent to be contacted by Gilead Sciences by electronic means (such as e-mail or SMS) with information about products and services programs which we feel may be of interest to you.

You have the right to opt out of receiving such electronic communications, at any time, by selecting the unsubscribe option at the footer of our communications.

We may share your personal data with other Gilead Sciences affiliates and/or third-party vendors providing services to Gilead Sciences. We shall always remain responsible for the confidentiality and security of your personal data.

This material is for healthcare professionals practicing in Middle East only.

Reporting suspected adverse reactions of medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via:

Kuwait/UAE: the national reporting schemes as applicable.

Saudi Arabia: the National Pharmacovigilance Centre (NPC) unified number: 19999 or email: npc.drug@sfda.gov.sa

Adverse reactions may also be reported directly to Gilead.
Adverse reactions related to Gilead products may be reported directly to Gilead via:

Kuwait: drugsafety@warbamed.com
UAE/Saudi Arabia: Safety_FC@gilead.com